Recent

% | $
Quotes you view appear here for quick access.

SIGA Technologies Inc. Message Board

  • agen_follower agen_follower Mar 27, 2014 4:24 PM Flag

    amln....golongin

    ...do you have any SRPT?...if not,why not?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Sorry Agen....Fghton is my other Yahoo alias ID since 2002....Seldom use it...

    • Hi Agen.... Owned a lot of it from the 12's from the day it crashed last year when the FDA said they would have to run some trials to get their drug approved. Sold it when it hit $20 and then watched it go much higher.
      Think you will see some of my posts on that Board if you go back far enough.

      This may sound corny but I love the drug and the families who support it simply for moral reasons.
      It is really the only drug I can think of that is outright compelling for use on these poor children who have
      been born literally with a death sentence. It seems to have a good safety profile, and it has been shown to improve these children's physical abilities quite a bit, even over time.

      With that said the market is extremely small unless they can show the drug can improve the lives
      of say adult MDA or MS patients. That and I don't trust that the FDA will approve the drug without some sort of
      Phase II/III trial....however small that might be.

      Bottom line might be it is getting in the interest zone price wise to me but ideally I'd probably like it under $20.

      • 1 Reply to fghton
      • Thanks golong...regarding small market I know is not ....exxon51 which sarepta is addressing, is 13 percent of the market...the drug as you know will be aggressively priced...to mimic the same results on the other exxons is relatively easy ...if, god willing, eteplirsen is approved the market with the rest of the other exxons will be huge..and this is just for dmd..maybe 5 billion..maybe more....it is early innings...I appreciate your posts.....as always intelligent and honest.

 
SIGA
2.460.00(0.00%)Mar 13 4:00 PMEDT